BASF upping cost of ethanolamines by €100 per tonne in Europe

By Dan Stanton

- Last updated on GMT

Image: iStock/Gabriele Maltinti
Image: iStock/Gabriele Maltinti

Related tags Active ingredient

BASF will increase the European sales prices for its ethanolamines by €100 ($110) per metric ton due to the rising costs of the raw material.

Ethanolamines (EOA) compounds are used in the pharmaceutical industry for the production of a wide range of active pharmaceutical ingredients (APIs) and excipients, as well as being an important chemical in a number of other industries.

But with immediate effect, European drugmakers will now have to pay an extra €100 for each metric ton of monoethanolamine (MEOA), diethanolamine (DEOA) and triethanolamine (TEOA), the firm said today.

Company spokeswoman Dandan Wang told the “reason for the price increase is the consecutive increase of raw material prices,” ​but would not disclose what percentage the extra €100 per mt represents.

She did, however, dismiss the price hike is related to a deadly explosion at its Ludwigshafen, Germany site​ earlier this month which led to the firm halting production at 20 manufacturing plants across the site.

As well as Ludwigshafen, BASF manufactures ethanolamines at its sites in Antwerp, Belgium, and Nanjing, China.

The price increase will apply to current supply agreements as soon as, and to the extent permitted by, the terms and conditions of the customer contracts.

The cost of ethanolamines has continued to rise yearly, though the €100 increase is almost twice that of the hike in 2015​ and – for some EOAs – five time that of the increase in 2014​.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more